Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: A propensity score matched cohort study

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 695-704

  Min, Y W ^a   Lim, K S ^a   Min, B H ^a   Gwak, G Y ^a   Paik, Y H ^a   Choi, M S ^a   Lee, J H ^a   Kim, J J ^a   Koh, K C ^a   Paik, S W ^a   Yoo, B C ^a   Rhee, P L ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT INDICATION;

AGED; ASCITES; BACTERIAL INFECTIONS; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; PROPENSITY SCORE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84906252848     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12875     Document Type: Article

References (46)

1. Targownik LE, Metge C, Roos L, Leung S,. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 2007; 102: 942-50.
2. Wolfe MM, Soll AH,. The physiology of gastric acid secretion. N Engl J Med 1988; 319: 1707-15.
3. Katz PO, Gerson LB, Vela MF,. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-28; quiz 329.
4. Poynard T, Lemaire M, Agostini H,. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5.
5. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ,. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86.
6. Bader JP, Delchier JC,. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 47-52.
7. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al,. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE 2012; 7: e50836.
8. Johnstone J, Nerenberg K, Loeb M,. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165-77.
9. Yu EW, Bauer SR, Bain PA, Bauer DC,. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124: 519-26.
10. Ho PM, Maddox TM, Wang L, et al,. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
11. Wiest R, Krag A, Gerbes A,. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61: 297-310.
12. Wiest R, Garcia-Tsao G,. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
13. Bauer TM, Steinbruckner B, Brinkmann FE, et al,. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.
14. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY,. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-8.
15. Pardo A, Bartoli R, Lorenzo-Zuniga V, et al,. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-63.
16. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA,. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002; 35: 622-9.
17. Obstein KL, Campbell MS, Reddy KR, Yang YX,. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol 2007; 102: 2732-6.
18. Lewis SJ, Franco S, Young G, O'Keefe SJ,. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557-61.
19. Bajaj JS, Zadvornova Y, Heuman DM, et al,. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-4.
20. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM,. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011; 65: 674-8.
21. Campbell MS, Obstein K, Reddy KR, Yang YX,. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008; 53: 394-8.
22. D'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
23. Cheong HS, Kang CI, Lee JA, et al,. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 1230-6.
24. Hill J,. Discussion of research using propensity-score matching: comments on 'A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003' by Peter Austin, Statistics in Medicine. Stat Med 2008; 27: 2055-61; discussion 2066-9.
25. Chang CS, Chen GH, Lien HC, Yeh HZ,. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28: 1187-90.
26. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD,. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10: 422-7.
27. Caruntu FA, Benea L,. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointest Liver Dis 2006; 15: 51-6.
28. Sheer TA, Runyon BA,. Spontaneous bacterial peritonitis. Dig Dis 2005; 23: 39-46.
29. Miner PB Jr, Allgood LD, Grender JM,. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther 2007; 25: 103-9.
30. Chey WD, Mody RR, Wu EQ, et al,. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009; 25: 1869-78.
31. Lee KJ, Kim JI, Park JS, et al,. Practice pattern of gastroenterologists for the management of GERD under the minimal influence of the insurance reimbursement guideline: a multicenter prospective observational study. J Korean Med Sci 2011; 26: 1613-8.
32. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J,. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31.
33. Llach J, Rimola A, Navasa M, et al,. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724-7.
34. Andreu M, Sola R, Sitges-Serra A, et al,. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 1133-8.
35. Senzolo M, Cholongitas E, Burra P, et al,. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189-93.
36. Fernandez J, Navasa M, Planas R, et al,. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
37. Gines P, Rimola A, Planas R, et al,. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716-24.
38. Choi EJ, Lee HJ, Kim KO, et al,. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011; 46: 616-20.
39. Castellote J, Xiol X, Verdaguer R, et al,. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990; 85: 1605-8.
40. Wells CL,. Relationship between intestinal microecology and the translocation of intestinal bacteria. Antonie Van Leeuwenhoek 1990; 58: 87-93.
41. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA,. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8.
42. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC,. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-9.
43. Nerandzic MM, Pultz MJ, Donskey CJ,. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile nfection. Antimicrob Agents Chemother 2009; 53: 4133-7.
44. Leontiadis GI, Miller MA, Howden CW,. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012; 107: 1020-1.
45. Sarkar M, Hennessy S, Yang YX,. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-8.
46. de Jager CP, Wever PC, Gemen EF, et al,. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012; 36: 941-9.